Balanced news tone
News Sentiment
OKUR sentiment intelligence
OnKure Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
55
Balanced news tone
40 relevant articles
Price is moving more forcefully than the current news tone suggests.
78/100 classification confidence.
directly relevant articles
high-authority source matches
-6.6% over one week, +1.9% over four weeks, trend active, and near fair-value range.
Enterprise value to revenue forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
78/100 classification
One-week reaction
-6.6%
Price reacting lower
Trend fit
Trend active
1.9% over four weeks
Fair value
-14.4%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
10
Neutral
28
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
simplywall.st
Direct company coverage
Is OnKure Therapeutics (NASDAQ:OKUR) In A Good Position To Deliver On Growth Plans?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Jul 2025 07:00
- Source
- simplywall.st
Stock Titan
Direct company coverage
OKUR Stock Price, News & Analysis
OnKure Therapeutics (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on precision medicines for cancers driven by PI3Kα mutations, with its lead candidate OKI-219 in Phase 1 clinical trials for advanced solid tumors. The company is also developing a broader PI
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 06 May 2025 00:08
- Source
- Stock Titan
MarketBeat
Direct company coverage
OnKure Therapeutics (OKUR) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Oct 2024 15:08
- Source
- MarketBeat
TradingView
Direct company coverage
OKUR Stock Price and Chart — NASDAQ:OKUR
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Oct 2024 13:49
- Source
- TradingView
Market source
Direct company coverage
OnKure and Reneo Pharmaceuticals complete merger
OnKure and Reneo Pharmaceuticals have successfully completed their merger, with the combined company now operating as OnKure Therapeutics. The new entity's shares will trade on Nasdaq under the ticker "OKUR" following an all-stock deal and a $65 million private placement. The mer
- Tone
- Positive 71/100
- Event
- Deals and strategy
- Published
- 07 Oct 2024 07:31
- Source
- Market source
GlobeNewswire
Direct company coverage
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure
Reneo Pharmaceuticals announced that its stockholders approved all proposals for the merger with OnKure, Inc., which is expected to close around October 4, 2024. Following the merger, the combined company will be named OnKure Therapeutics, Inc., trade under the ticker "OKUR" on N
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 02 Oct 2024 23:11
- Source
- GlobeNewswire
Market source
Direct company coverage
Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results
Reneo Pharmaceuticals reported a net loss of $5.4 million for the second quarter of 2024, a significant improvement from $19.5 million in the same period of 2023. The company is in the process of merging with OnKure, Inc. in an all-stock transaction, which is expected to close in
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Aug 2024 20:39
- Source
- Market source
Wilson Sonsini
Direct company coverage
Wilson Sonsini Advises Reneo Pharmaceuticals on IP Matters Related to OnKure Merger
Wilson Sonsini Goodrich & Rosati advised Reneo Pharmaceuticals on intellectual property matters concerning its definitive merger agreement with OnKure, Inc. This all-stock transaction will combine the two biopharmaceutical companies with a focus on advancing OnKure’s oncology pip
- Tone
- Positive 65/100
- Event
- Deals and strategy
- Published
- 15 May 2024 15:09
- Source
- Wilson Sonsini
Fierce Biotech
Direct company coverage
OnKure hitches Reneo's ride to Nasdaq in merger, with $65M PIPE to boot
OnKure Therapeutics has merged with Reneo Pharmaceuticals in a reverse merger, bringing $120 million and a breast cancer treatment pipeline to the Nasdaq under the ticker "OKUR." The deal includes a $65 million PIPE financing, with Reneo needing to maintain $55 million in cash, p
- Tone
- Positive 72/100
- Event
- Deals and strategy
- Published
- 13 May 2024 10:36
- Source
- Fierce Biotech
Market source
Direct company coverage
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
Reneo Pharmaceuticals and OnKure, a clinical-stage biopharmaceutical company, have announced a definitive merger agreement in an all-stock transaction. The combined entity, to be named OnKure Therapeutics, Inc., will focus on advancing OnKure's oncology pipeline, including its le
- Tone
- Positive 72/100
- Event
- Deals and strategy
- Published
- 13 May 2024 08:10
- Source
- Market source